CTLA4 and classic Hodgkin lymphoma: Another checkpoint molecule that was therapeutically evaluated in cHL, even though only a few clinical trials have been performed, is CTLA4, which competes with CD28 for the binding of CD80 and CD86, thereby antagonizing T-cell activation [2].